LIVE
BAX
Baxter International Inc. · Healthcare - Medical Devices & Hospital Products
$19.89
+8.51% this month
VERSUS
⟷
COMPARE
BDX
Becton, Dickinson and Company · Healthcare - Medical Devices & Diagnostics
$143.98
-2.02% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
BAX
1
BDX
4
Comparison scoreboard
BDX LEADS 4/5AI Score
BAX 25.5
BDX ✓39.7
1Y Return
BAX -33.52%
BDX ✓-15.28%
Fwd P/E
BAX ✓10.36
BDX 10.92
Target Up.
BAX +3.27%
BDX ✓+23.56%
Op. Margin
BAX 6.03%
BDX ✓14.74%
Metrics last refreshed: 6/20/2026
Quick take
BAX vs BDX Stock Comparison: AI Score, Valuation, Performance and Upside
BAX (Baxter International) and BDX (Becton Dickinson) are both large diversified medical products companies serving hospitals — Baxter focuses on critical care consumables (IV fluids, renal care) and hospital equipment (through Hill-Rom), while BD covers medication delivery, diagnostics, and interventional products. Both have made major acquisitions creating integration complexity and elevated debt; both serve hospital systems with products that range from highly differentiated to commodity consumables.
BAX vs BDX is critical hospital consumables and smart bed equipment with recovery execution risk (Baxter's essential IV fluid position and Hill-Rom hospital equipment facing manufacturing disruption recovery and high post-acquisition debt) versus diversified medical technology with safety device regulatory moats and diagnostics installed base (BD's safety-engineered syringes mandated by OSHA, blood culture systems creating sticky laboratory revenue, and broad hospital product portfolio with simplification strategy) — critical consumables recovery story versus diversified med-tech with regulatory moats.
Live analysis · updated 6/20/2026
BDX holds the edge across 4 of 5 key metrics in this comparison. BDX has delivered stronger 1-year price return (-15.28% vs -33.52%), though BAX trades at the lower forward P/E (10.36x vs 10.92x). BDX leads on both revenue growth (5.20%) and operating margin (14.74%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for BDX (+23.56%) than for BAX (+3.27%).
Normalized 1Y performance
BAX
BDX
Recent returns
BAX
BDX
Analyst price targets & sentiment
BAX
Price target range
analyst mean$21.54
current price$19.89
+3.3% upside to analyst mean
BDX
Price target range
analyst mean$180.69
current price$143.98
+23.6% upside to analyst mean
Who should consider this stock?
BAX may suit investors who:
- →See Baxter's IV fluid market position and Hill-Rom smart hospital equipment as durable healthcare assets trading at a discount due to temporary Hurricane Helene disruption and elevated acquisition debt
- →Believe Baxter's post-Vantive spinoff focus on hospital products simplifies the business and allows management attention on recovering IV production capacity and deleveraging the balance sheet
- →Value the essential, inelastic nature of IV fluids (approximately 40% of U.S. hospital IV supply) as providing stable baseline demand regardless of healthcare spending trends
BDX may suit investors who:
- →Want a diversified medical technology company with regulatory moats from OSHA-mandated safety syringe requirements and a sticky diagnostics installed base generating recurring laboratory revenue
- →Value BD's systematic divestiture and simplification strategy as improving operational focus and the quality of the remaining business over time
- →Prefer BD's more stable, less disruption-prone revenue profile versus Baxter's recent operational challenges from manufacturing concentration and acquisition integration
Performance & AI score
| Metric | BAX | BDX |
|---|---|---|
| AI score | 25.5 | 39.7 |
| AI rank | #2753 | #1135 |
| Latest close | $19.89 | $143.98 |
| 1M return | +8.51% | -2.02% |
| 6M return | +3.11% | -26.30% |
| 1Y return | -33.52% | -15.28% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | BAX | BDX |
|---|---|---|
| 1Y ago | $6.67K (-33.3%) started 2025-06-18 | $8.54K (-14.6%) started 2025-06-18 |
| 5Y ago | $2.92K (-70.8%) started 2021-06-21 | $6.87K (-31.3%) started 2021-06-21 |
| 10Y ago | $5.94K (-40.6%) started 2016-06-20 | $11.37K (+13.7%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | BAX | BDX |
|---|---|---|
| Market cap | $10.77B | $40.3B |
| Trailing P/E | 87.85 | 25.52 |
| Forward P/E | 10.36 | 10.92 |
| Price/Sales | N/A | N/A |
| EV/Revenue | 1.63 | 2.55 |
| Analyst target | $21.54 | $180.69 |
| Target upside | +3.27% | +23.56% |
Growth, profitability & risk
| Metric | BAX | BDX |
|---|---|---|
| Revenue growth | 2.90% | 5.20% |
| Earnings growth | 237.90% | 28.60% |
| EPS growth | +237.90% | +28.60% |
| FCF margin | +7.96% | +20.39% |
| Operating margin | 6.03% | 14.74% |
| Profit margin | -9.70% | 5.12% |
| ROIC proxy | -15.01% | 6.67% |
| Return on equity | -15.01% | 6.67% |
| Dividend yield | 0.96% | 2.87% |
| Beta | 0.64 | 0.28 |
| Debt/equity | 161.02 | 71.60 |
| Current ratio | 1.85 | 0.94 |
| Quick ratio | 1.02 | 0.35 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
BAX max drawdown49.41%
BDX max drawdown32.57%
BAX max wkly drop24.85%
BDX max wkly drop16.86%
5Y risk snapshot
BAX max drawdown80.87%
BDX max drawdown48.60%
BAX max wkly drop24.85%
BDX max wkly drop20.00%
10Y risk snapshot
BAX max drawdown81.40%
BDX max drawdown48.60%
BAX max wkly drop24.85%
BDX max wkly drop20.00%
Performance metrics by period
| Period | Metric | BAX | BDX |
|---|---|---|---|
| 1Y | Growth | -33.26% | -14.60% |
| CAGR | -33.29% | -14.62% | |
| Sharpe ratio | -0.72 | -0.52 | |
| Max drawdown | 49.41% | 32.57% | |
| Max daily drop | 22.42% | 17.22% | |
| Max wkly drop | 24.85% | 16.86% | |
| 5Y | Growth | -73.37% | -35.14% |
| CAGR | -23.28% | -8.31% | |
| Sharpe ratio | -0.74 | -0.41 | |
| Max drawdown | 80.87% | 48.60% | |
| Max daily drop | 22.42% | 18.13% | |
| Max wkly drop | 24.85% | 20.00% | |
| 10Y | Growth | -49.01% | -0.45% |
| CAGR | -6.52% | -0.04% | |
| Sharpe ratio | -0.23 | -0.07 | |
| Max drawdown | 81.40% | 48.60% | |
| Max daily drop | 22.42% | 18.13% | |
| Max wkly drop | 24.85% | 20.00% |
Business comparison
| Category | BAX | BDX |
|---|---|---|
| Company | Baxter International Inc. | Becton, Dickinson and Company |
| Sector | Healthcare | Healthcare |
| Industry | N/A | N/A |
| Core business | Baxter International provides critical care products for hospitals and patients — IV solutions and parenteral nutrition (the company produces approximately 40% of IV bags used in U.S. hospitals), peritoneal dialysis and hemodialysis products for kidney failure patients, acute care pharmaceuticals, and hospital equipment from its 2021 Hill-Rom acquisition (smart hospital beds, patient monitoring, nurse call systems). Baxter spun off its kidney care business as Vantive in 2024. | Becton Dickinson (BD) is a global medical technology company with three business segments: BD Medical (medication delivery including syringes, catheters, IV sets, drug delivery systems); BD Diagnostics (specimen collection, microbiology, laboratory automation); and BD Interventional (surgery, urology, peripheral intervention). BD is a leading manufacturer of safety-engineered syringes and needles, blood culture systems, and specimen collection devices. BD has completed major acquisitions including CareFusion (2015) and C.R. Bard (2017). |
| Investor focus | Investors track Baxter's hospital products revenue and margins, IV supply chain reliability (Baxter's manufacturing concentration in North Carolina was severely disrupted by Hurricane Helene in 2024), post-Hill-Rom integration execution, the Vantive kidney care spinoff impact, and debt reduction from high acquisition-related leverage. | Investors track BD's organic revenue growth across its three segments, margin expansion from efficiency programs, the Biosciences and Advanced Patient Monitoring spinoffs, and debt deleveraging from the C.R. Bard acquisition. BD has pursued a multi-year simplification strategy, divesting non-core businesses. |
BAX strengths
- →Critical IV fluids position in U.S. hospitals — Baxter produces approximately 40% of IV bags used in U.S. hospitals; IV fluids are an essential, inelastic hospital supply with no close substitute; this position creates durable revenue though at modest margins
- →Hill-Rom smart hospital bed and patient monitoring integration — Hill-Rom's Progressa and Centrella smart beds and nurse call communication systems are sticky installed-base products that generate recurring service and upgrade revenue from hospitals committed to the platform
- →Renal care expertise (through Vantive spinoff) developed over decades — Baxter pioneered peritoneal dialysis and built a global renal care franchise; the Vantive spinoff allows Baxter to focus on hospital products while Vantive pursues the kidney care market independently
BDX strengths
- →Market leadership in safety syringes and needlestick prevention — BD's Safety-Lok and other safety-engineered injection devices are mandated by OSHA needlestick prevention regulations; this regulatory driver creates mandatory demand for BD's products
- →Blood culture and microbiology diagnostics installed base — BD's BACTEC blood culture systems and Phoenix antimicrobial susceptibility testing create a sticky diagnostics installed base in hospital laboratories; hospitals invested in BD platforms replace instruments with next-generation BD products
- →Scale across medication delivery, diagnostics, and interventional — BD's breadth across multiple clinical care pathways diversifies revenue across hospital departments and creates cross-selling opportunities
Risks to watch — BAX
- →Hurricane Helene manufacturing disruption — Baxter's Marion, North Carolina facility (a major IV fluid production site) was severely damaged by Hurricane Helene in fall 2024, creating significant IV supply shortages across U.S. hospitals; the magnitude and duration of this disruption materially impacted Baxter's business and the U.S. healthcare system
- →High debt burden from Hill-Rom acquisition — the $10.5B Hill-Rom acquisition created significant debt that Baxter must reduce through operating cash flow; high leverage constrains financial flexibility and creates earnings headwinds
- →Hill-Rom integration complexity — combining Baxter's hospital products culture with Hill-Rom's smart hospital equipment business required significant operational integration; the combined company faces execution challenges across product portfolios
Risks to watch — BDX
- →Organic revenue growth execution — BD's complexity across numerous product lines and markets creates execution challenges; the company must demonstrate consistent mid-single-digit organic revenue growth to justify its valuation
- →Currency headwinds — BD's large international business (~50% of revenue) creates significant foreign exchange translation risk; dollar strengthening reduces reported revenue and earnings meaningfully
- →Innovation pipeline investment requirements — maintaining market leadership across syringes, diagnostics, and interventional requires ongoing R&D investment; BD must continually introduce next-generation products to prevent commoditization of its installed base
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →